Skip to content

Clinical study of anticoagulant efficacy and safety of two topical citrate anticoagulant regimens in hemodialysis patients: an open, single-center randomized controlled study

Clinical study of anticoagulant efficacy and safety of two topical citrate anticoagulant regimens in hemodialysis patients

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200061027
Enrollment
Unknown
Registered
2022-06-15
Start date
2022-06-01
Completion date
Unknown
Last updated
2023-03-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Renal insufficiency

Interventions

group A :Single segment RCA scheme
group B :Two - segment RCA scheme

Sponsors

The Second Affiliated Hospital of Nanchang University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Patients requiring routine hemodialysis (HD) due to renal insufficiency; 2. Aged 18-70 yeas; 3. Heparin or low molecular weight heparin should not be used for anticoagulation in patients with active bleeding in vivo or with high risk of bleeding (such as gastrointestinal bleeding, cerebral hemorrhage, or bleeding at the surgical site); 4. The hemoglobin level is 70-120g /L; 5. Platelet level (100-350) x 10^9/L; 6. Blood calcium level is 1.8 to 2.5mmol/L; 7. Vascular access for arteriovenous fistula or deep vein indwelling catheter; 8. Hemodynamic stability; 9. Clear consciousness; 10. Normal cognitive ability, high compliance and willing to sign informed consent.

Exclusion criteria

Exclusion criteria: 1. Have a history of sodium citrate allergy; 2. History of cirrhosis or obvious liver function damage; 3. Extensive muscle tissue injury or muscle tissue insufficiency; 4. Need to mask oxygen or oxygenation index < 300mmHg. 5. Hemophilia or other history of coagulation; 6. The presence of systemic serious infection; 7. Patients with mental disorders can not cooperate with the treatment; 8. Other clinicians think that the overall condition is serious or obvious fluctuations.

Design outcomes

Primary

MeasureTime frame
Hemodialyzer and tube coagulation events;

Secondary

MeasureTime frame
Blood gas analysis;Routine blood;The biochemical indicators;Blood coagulation indexes;iCa2+ clearance;

Countries

china

Contacts

Public ContactChong Huang
240364412@qq.com+86 18070059811

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026